Timing of Immune-Related Adverse Events with Relation to IL-2 Treatment

irAEs/Total Patients (%)Prior to IL-2During IL-2After IL-2
Total152/1535 (8.4%)312497
mM99/623 (16%)161271
mRCC53/920 (5.8%)151226
Total irAEs312497
Related to IL-2NADuring and after IL-274
Undetermined if Related to IL2 or CPINA15
Related to CPINA24

mM metastatic melanoma, mRCC metastatic renal cell cancer, irAEs immune-related adverse events, IL-2 interleukin-2, CPI checkpoint inhibitor, NA - not applicable